Blood Flow, Oxygen and Nutrient Supply, and Metabolic Microenvironment of Human Tumors: A Review

Peter Vaupel, Friedrich Kallinowski, and Paul Okunieff

Department of Radiation Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114

Abstract

The objective of this review article is to summarize current knowledge of blood flow and perfusion-related parameters, which usually go hand in hand and in turn define the cellular metabolic microenvironment of human malignancies. A compilation of available data from the literature on blood flow, oxygen and nutrient supply, and tissue oxygen and pH distribution in human tumors is presented. Whenever possible, data obtained for human tumors are compared with the respective parameters in normal tissues, isotransplanted or spontaneous rodent tumors, and xenografted human tumors. Although data on human tumors in situ are scarce and there may be significant errors associated with the techniques used for measurements, experimental evidence is provided for the existence of a compromised and anisotropic blood supply to many tumors. As a result, O2-depleted areas develop in human malignancies which coincide with nutrient and energy deprivation and with a hostile metabolic microenvironment (e.g., existence of severe tissue acidosis). Significant variations in these relevant parameters must be expected between different locations within the same tumor, at the same location at different times, and between individual tumors of the same grading and staging. Furthermore, this synopsis will attempt to identify relevant pathophysiological parameters and other related areas future research of which might be most beneficial for designing individually tailored treatment protocols with the goal of predicting the acute and/or long-term response of tumors to therapy.

Introduction

A great number of malignancies are relatively resistant to radiotherapy, chemotherapy, and other nonsurgical treatment modalities. A variety of factors are involved in the lack of responsiveness of these neoplasms including an intrinsic, genetically determined resistance and physiological, extrinsic (epigenetic, environmental) factors primarily created by inadequate and heterogeneous vascular networks (1–5). Thus properties such as tumor blood flow, tissue oxygen and nutrient supply, pH distribution, and bioenergetic status, factors which usually go hand in hand, can markedly influence the therapeutic response. Data on these parameters are mostly derived from rodent tumors (for references see 6–12). However, fast-growing rodent tumors might not adequately represent the multitude of neoplastic growths encountered in patients. Unfortunately, data on human tumors in situ are scarce and there may be significant errors associated with the techniques used for measurements. This should be kept in mind when comparing available results from the literature.

In order to create a factual basis for further research, the currently available information on tumor blood flow, tissue oxygen distribution, nutrient supply, and metabolic micromilieu is compiled in this review. This synopsis attempts to identify areas in which future research might be most beneficial (e.g., for designing specifically tailored treatment protocols for individual subjects, for assessing early tumor response to treatment, and/or for examining potentially useful tools for prediction of long-term tumor response).

Vasculature and Blood Flow of Human Tumors

Vascularization of Tumors

The establishment and progressive expansion of malignant tumors following the avascular growth period are possible only if convective nutrient supply and waste removal are initiated through nutritive blood flow, i.e., flow through tumor microvessels that guarantees adequate exchange processes between the microcirculatory bed and the cancer cells. When considering the origin of blood vessels in a growing tumor, one must take into account the existence of two different populations: (a) preexisting host vessels which are incorporated into the tumor tissue; and (b) tumor microvessels arising from neovascularization due to the influence of tumor angiogenesis factor(s).

In the preexisting, normal host vasculature which provides the structures from which neovascularization arises and which can fulfill microcirculatory functions for certain time periods in given locations within a tumor, a series of morphological and functional changes occur. First, the venules become tortuous, elongated, and often dilated. The host vessels per unit tumor mass do not increase in number, thus leading to a reduction of the available exchange area for oxygen, nutrients, hormones, growth factors, and waste products (e.g., hydrogen ions, lactic acid, necrosis products). During growth, some of the preexisting host vessels incorporated in the tumor mass disintegrate, are obstructed, or are compressed. The remaining vessels seem to remain functionally intact and probably maintain the ability to respond to physiological and pharmacological stimuli. This holds especially true for the arterial vessels which seem to be permanently dilated and somehow “resistant” to the invasive and destructive growth of cancer cells. Spontaneous vasomotion, a typical feature of normal tissues, is mostly lacking in tumor arterioles (for reviews see Refs. 2, 9, and 13–16).

Neovascularization in tumors usually originates from venules within the tumor mass or from venules of the host tissue adjacent to the invasion front. Vascular buds and sprouts grow out from the venular sites. These soon begin to show lumen and randomly fuse, giving rise to loops and anastomosing with arteriolar vessels. At this point blood perfusion through the newly formed microvessels can begin. Occasionally, venular sprouts anastomose with other venules, so that the newly formed vascular network is both supplied and drained by venules.

Whether or not the patterns of the newly formed vascular networks are characteristic for different tumor types is still an open question (for reviews see Refs. 17 and 18). Newly formed
microvessels of some of the highly differentiated tumors can have a mature architecture. In contrast, the hastily formed new tumor microvessels in rapidly growing tumors show a series of severe structural abnormalities. The most relevant of these vascular abnormalities are listed in Table 1. From the fact that hypoxic and ischemic areas can be evident during very early growth stages of (xenografted) human tumors, it might be concluded that the morphological appearance of the tumor vascular bed does not necessarily allow direct judgments concerning functional aspects of the tumor microcirculation or of the nutritive tumor microflow. This is due to the fact that, in very early growth stages, serious functional disturbances of the microflow are already manifest. Some of these are listed in Table 1. This should be stressed, since vascular morphometry and diagnostic X-ray angiography are often improperly used for prospective estimations of tumor radiosensitivity or local pharmacokinetics. A high vascular density is a prerequisite for but is not necessarily indicative of a high nutritive flow.

There are some indications that considerable spatial and temporal heterogeneity of the microcirculation exists among individual vessels and different microareas within one tumor, in the same tumor line at different sizes or at different growth sites, between different tumor lines with the same grading and staging, as well as between tumors of different histologies.

**Tumor Blood Flow**

**Perfusion Rate of Human Tumors.** Whereas blood flow rates of most isotransplanted rodent tumors decrease with increasing tumor size, a similar relationship has not been found to be valid for all human tumors (for reviews see Refs. 6, 9, and 11). Whether the latter indicates a lack of sufficient data or a fundamental deviation from isografted tumors is unclear at this time. Considering the pathogenetic mechanisms directly responsible for the weight-adjusted flow decline that occurs with tumor growth, (a) a progressive rarefaction of the vascular bed, i.e., a decrease in the number of patent vessels per g of tumor, (b) severe structural and functional abnormalities of the tumor microcirculation, and (c) the development of necrosis must be taken into account. These disturbances of tumor microcirculation are apparent even at early growth stages and, at least in iso- or xenografted rodent tumor models, become more pronounced with tumor growth (for references see Refs. 9 and 19-21). As a rule, the blood supply to animal tumors is spatially heterogeneous on a macro- and a microscopic scale. In addition, there is a pronounced temporal heterogeneity within a tumor and a tremendous variability among individual tumors of the same line.

Measurements of blood flow in a series of xenotransplanted human tumors in immunodeficient animals exhibited a 10-fold variation in weight-adjusted tumor perfusion indicating large variations in angiogenesis. Flow values obtained were consistent with data from clinical observations of human tumors in situ and were within the range of that of normal tissues (tissues of origin) at different conditions of functional activity (22, 23). In an experimental model of a human medulloblastoma, two distinct tumor patterns were observed, depending on both histology and blood flow (24). In tumors with a solid mass of tumor cells and limited infiltration of the brain around the tumor, blood flow values were lower than in brain cortex or in the contralateral corpus callosum. In contrast, infiltrative tumors characterized by cells growing only perivascularly had blood flows significantly higher than in tumor-free white matter but lower than in normal cortex.

Global tumor perfusion (blood flow) has been measured in patients using various techniques. To date, none of the approaches used to measure tumor perfusion provide the information needed on the events occurring at the microscopic level. Furthermore, they cannot give detailed data on arteriovenous shunt perfusion. Methods used for blood flow measurements in human tumors include steady-state inhalation of C15O2 and positron emission tomography,1 hydrogen and isotope clearance techniques (85Kr, 133Xe) and thermal washout procedures. Since in the latter case heat transport by conduction is not negligible, especially in superficial tumors, the blood flow rate calculated contains a systematic error which, under low-flow conditions, can vary between different experimental conditions and can be quite large in absolute values. In the case of isotope clearance techniques, the indicator generally is applied topically, i.e., into the tumor mass, which can lead to tremendous perturbations of the local microcirculation due to an increase in intratumor pressure.

For comparison the blood supply to normal organs, and of tumors is given in Fig. 1 using specific perfusion rate units (ml/g/min) (25). These are average values, from which there may be departures in individual cases. Moreover, the specific perfusion may vary considerably in different parts of an organ (e.g., renal cortex versus medulla, subendocardial versus subepi-

---

<table>
<thead>
<tr>
<th>A. Structural abnormalities (&quot;vascular chaos&quot;)</th>
<th>B. Functional abnormalities (&quot;circulatory chaos&quot;)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Abnormal vessel wall</td>
<td>1. Consequences of altered morphology</td>
</tr>
<tr>
<td>- Incomplete or missing endothelial lining</td>
<td>- Arteriovenous shunt perfusion (&gt; 30%)</td>
</tr>
<tr>
<td>- Interrupted or absent basement membrane</td>
<td>- Regurgitation and intermittent flow</td>
</tr>
<tr>
<td>- Blood channels lined by tumor cell cords</td>
<td>- Unstable speed and direction of flow</td>
</tr>
<tr>
<td>- Lack of pericytes, contractile wall components, and pharmacological/physiological receptors</td>
<td>- Absence of vasomotion</td>
</tr>
<tr>
<td></td>
<td>- Increased vascular fragility</td>
</tr>
<tr>
<td></td>
<td>- Obstruction of microvessels by WBC and tumor cells</td>
</tr>
<tr>
<td></td>
<td>- High tumor vascular (geometric) resistance</td>
</tr>
<tr>
<td>2. Abnormal vascular architecture</td>
<td>2. Consequences of altered rheology</td>
</tr>
<tr>
<td>- Contour irregularities (formation of lacuna-like, sinusoidal, and cystiform blood vessels)</td>
<td>- RBC sludging, leukocyte sticking</td>
</tr>
<tr>
<td>- Tortuosity (distortions, twisting, bending)</td>
<td>- Platelet aggregation</td>
</tr>
<tr>
<td>- Elongation of vessels</td>
<td>- Micro- and macrothrombosis</td>
</tr>
<tr>
<td>- Existence of arteriovenous shunts (global flow &gt; nutritive flow)</td>
<td>- Increase of viscous resistance</td>
</tr>
<tr>
<td>- Loss of hierarchy</td>
<td></td>
</tr>
<tr>
<td>3. Abnormal vascular density</td>
<td>3. Consequences of increased vascular permeability</td>
</tr>
<tr>
<td>- Heterogeneous distribution of vascularization (&quot;chaotic network,&quot; appearance of avascular areas)</td>
<td>- Hemoconcentration</td>
</tr>
<tr>
<td>- Expansion of the intercapillary space (increase of diffusion distances)</td>
<td>- Significant interstitial bulk flow</td>
</tr>
<tr>
<td></td>
<td>- High interstitial fluid pressure (with compression of tumor microvessels)</td>
</tr>
<tr>
<td></td>
<td>- Blood cell extravasation, hemorrhage</td>
</tr>
<tr>
<td></td>
<td>- Increase of viscous resistance</td>
</tr>
</tbody>
</table>

---

1. The C15O2 PET technique is based on the exchange of water in the tissue; thus shunt perfusion should virtually be excluded.
cardiac regions of the myocardium, white matter versus gray matter of the brain), and under different conditions of activity (e.g., heart at rest or during strenuous exercise, skeletal muscle at rest or during hard work, skin in a cold environment and during heat load).

The blood flow of malignant tumors in humans has been studied using radioactive $^{99m}$Y microspheres while treating patients (26). In this study, the amount of blood flowing to tumors was estimated and compared to the blood supply of normal tissues at the site of tumor growth. This “qualitative” investigation demonstrated a normal tissue flow/tumor flow ratio in the range of 3/1 to 30/1. Primary tumors tended to have a better blood supply than metastatic lesions, and peripheral tumor areas showed a higher flow rate than more central portions. These data imply that tumor blood flow may be considerably lower than normal tissue perfusion. Such a conclusion, however, certainly requires a more precise understanding of tumor pathophysiology and a larger data base on human tumor blood flow.

A number of studies on blood flow through human tumors have been reported since this pioneering study in 1966. Most of them are more or less casuistic reports rather than systematic investigations; therefore definite conclusions cannot be drawn. Flow studies were performed on brain tumors (27-39), breast cancers (27, 40, 41), metastatic lesions (36-38, 42-46), anaplastic carcinomas, differentiated tumors and lymphomas (27, 47, 48), carcinomas of the uterus (49), adenocarcinomas* and squamous cell carcinomas (50, 51), melanomas (50), liver tumors (52), lymphangiomas (53), and osteosarcomas (42).

Considering all presently available data on human tumors in situ, the following (preliminary) conclusions can be drawn if flow data for the different tumor types are pooled: blood flow can vary considerably despite similar histological classification and primary site; tumors can have flow rates which are similar to those measured in tachytrophic organs (i.e., in organs with a high metabolic rate such as liver, heart, or brain); some tumors exhibit flow values which are even lower than those of bradytrophic tissues (i.e., of tissues with a low metabolic rate such as skin, resting skeletal muscle, or adipose tissue); blood flow in human tumors can be higher or lower than that of the tissue of origin, depending in the functional state of the latter tissue (e.g., average blood flow in breast cancers is substantially higher than that of postmenopausal breast and significantly lower than flow data obtained in the lactating, parenchymal breast); the average perfusion rate of carcinomas does not deviate substantially from that of sarcomas; and metastatic lesions exhibit a blood supply which is comparable to that of the primary tumors as long as comparable sizes are considered.

Due to methodological uncertainties, these preliminary conclusions should be confirmed in future studies. Blood flow measurement techniques of the future should be noninvasive and should allow for serial investigations. Current promising methodologies using radiation activation (a washout technique), NMR5 and computerized body tomography, angiographic and cinematographic techniques (flow imaging techniques) and other washout procedures (e.g., $^{201}$T1 and $^3$H2O) may achieve this goal.

Because of a pronounced variability within tumors of a given histology, a clear correlation between tumor type and specific blood flow rate is not obvious although in some studies flow differences were significant when different tumor types or tumors with different grades were compared. In a report on regional blood flow in human malignancies, Mäntylä (47) has reported statistically higher flow values in lymphomas than in

---

* M. Molls, unpublished observations.

---

Fig. 1. Variability of blood flow in human malignancies (W) and mean flow values of normal tissues (horizontal lines). Pooled data are given for the various tumors: primary brain tumors and metastatic tumors in the brain; lymphomas; differentiated tumors; breast cancers and squamous cell carcinomas (SCC); uterus tumors; various primary tumors; sarcomas, adenocarcinomas, and melanomas; anaplastic carcinomas; liver carcinomas. (The respective references are given in the text.)
anaplastic or differentiated carcinomas. Interestingly, no correlation between the size of the tumors and the blood perfusion rates was seen. This result agrees with some single observations of Tanaka (54) and Bru et al. (55). Considering tumors of different grades, Nyström et al. (49) measured significantly different flow values in low- and in highly differentiated carcinomas of the corpus uteri (0.4 versus 0.1 ml/g/min). However, blood flow variability may not necessarily correlate with tumor grade since astrocytomas of different grades exhibited similar mean flow values and great intertumor variability within one grade (see Table 2). In general, perfusion through astrocytomas was found to be extremely variable, but the mean value was close to that of the contralateral white matter. Flow ranged from virtually zero to values in excess of normal gray matter. No relationship between tumor perfusion and vascularity was found in a series of patients. This suggests that vascularity as judged by histological examination or angiography is an inadequate method of assessing nutritive blood flow (27, 36). In addition, the tumor size seems to have no significant influence on the specific perfusion rate of most tumors investigated to date (47).

Blood flow through tumors is anything but uniform. Most tumors contain both highly perfused areas, which are rapidly growing and which infiltrate the normal surroundings, and regions with compromised and sluggish perfusion, often associated with the development of necrosis.

Arteriovenous Shunt Perfusion in Tumors. First rough estimations concerning the arterovenous shunt flow in malignant tumors showed that at least 30% of the arterial blood can pass through experimental tumors without taking part in the microcirculatory exchange processes (59–61). In patients receiving intraarterial chemotherapy for head and neck cancer, shunt flow is reported to be 8–43% of total tumor blood flow, the latter consistently exceeding normal tissue perfusion of the scalp (51). The mean fractional shunt perfusion of tumors was 23 ± 13% (SE) in studies utilizing 99mTc-labeled macroaggregated albumin (diameter of the particles, 15–90 µm). The significance of this shunt flow on local pharmacokinetics, on the development of hypoxia, and on other relevant metabolic phenomena has not yet been studied systematically and remains speculative. For example, oxygen diffusion distances in poorly perfused human breast cancer xenografts using tumor-specific in vivo data have recently been evaluated by Groebe and Vaupel (62). In this study evidence is given that radiosensitivity may be less than 10% of maximum at intercapillary distances above 100 µm; if intercapillary distances exceed 140 µm, areas of radiobiologically hypoxic tissue are estimated to be 4% (or 8%) if a shunt perfusion of 20% (or 35%) is assumed.

Physiological and Pharmacological Responsiveness of Tumor Blood Vessels. Another open question deals with the responsiveness or reactivity of tumor microvessels to physiological and pharmacological stimuli. As already indicated, it is most likely that only the incorporated host vessels still exhibit some reactivity. Therefore, the existence and the extent of a microcirculatory regulation and the overall response of a tumor will depend on the prevalence as well as on the proportion of residual normal host vessels in a growing tumor. Most probably the vessels recruited from the preexisting vascular network are maximally dilated in poorly perfused tumors (as a result of tissue acidosis and hypoxia/anoxia). The ratio of host vessels to newly formed vessels can vary from one location to another and from one observation time to the next in the same tumor and from one tumor to another (19). Intratumor responsiveness can be feigned by steal phenomena and anti-steal phenomena in conjunction with the vascular bed of the normal host tissues adjacent to the tumor tissue.

The principle parameters determining the actual blood flow rate through the tumor vascular network are (a) perfusion pressure, (b) geometric resistance (governed by the vessel diameter), and (c) the viscous resistance which is determined predominantly by the rheological properties of the blood (19–21, 63). Hence, modifications of these three parameters may have the potential to modulate tumor blood flow rate. Whether or not a treatment advantage can be gained using the differential response of tumor blood flow to chemical (or pharmacological) agents is still an open question. Encouraging research results with some agents were obtained in animal studies and require clinical testing. Measurements of the vascular responsiveness of human tumors have been anecdotal, generally estimated via angiograms during diagnostic procedures. Effects of various vasodilators, of vasoconstrictors, and of chemical substances which can alter blood viscosity have been comprehensively reviewed by Jain and Ward-Hartley (6), Vaupel (9), Peterson (64), and Jirtle (65). The evidence presented in these reviews shows tremendous disparity making definitive conclusions impossible at the present time.

Convective Currents in the Interstitial Space of Tumors. Bulk flow of free water in the interstitial space of tumors is another characteristic pattern of malignant growth. Due to a high vascular permeability and due to the absence of a functioning lymphatic drainage system in many malignant tumors, there is a significant bulk flow of fluid in the interstitial space. Whereas in normal tissues, convective currents in the interstitial space are estimated to be about 0.4–1% of plasma flow in isografted or transplanted rat tumors bulk flow of free fluid was 3–7% of the plasma flow rate (19, 66). In xenografted human tumors interstitial water flux can be as high as 7–14% of the respective plasma flow (67). A significant hemoconcentration during tumor passage and thus a tremendous increase in viscous resistance is an obligatory consequence. This has been shown for both isografted and transplanted rodent tumors (68, 69) and xenografted human tumors (22). This pronounced bulk transfer of fluid in the interstitial space is accompanied by a high interstitial fluid pressure in the respective tumors which can cause a progressive vascular compression with growth (for a review see Ref. 66). Very likely the same holds true for tumors in patients, although this has not yet been shown experimentally.

### Table 2: Blood flow through normal human brain and through primary and metastatic brain lesions (pooled data)

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Blood flow (ml/g/min)</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astrocytomas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade I</td>
<td>0.03–0.43</td>
<td>28, 35, 37–39</td>
</tr>
<tr>
<td>Grade II</td>
<td>0.03–1.01</td>
<td></td>
</tr>
<tr>
<td>Grade III</td>
<td>0.26–0.98</td>
<td></td>
</tr>
<tr>
<td>Grade IV</td>
<td>0.15–1.02</td>
<td></td>
</tr>
<tr>
<td>Brain metastases</td>
<td>0.03–0.72</td>
<td>28, 33, 37, 38</td>
</tr>
<tr>
<td>Normal gray matter</td>
<td>0.25–0.78</td>
<td>27, 28, 33, 34, 37, 59–56</td>
</tr>
<tr>
<td>Normal white matter</td>
<td>0.08–0.33</td>
<td></td>
</tr>
</tbody>
</table>

### Oxygen Consumption Rates and Tumor Tissue Oxygenation

**Oxygen Consumption Rates of Human Tumors in Situ**

Cellular respiration was among the first processes to be investigated in early cancer biochemistry. The studies of War-
BLOOD FLOW AND METABOLISM OF HUMAN TUMORS

burg (70) resulted in his formulation of a pattern essential for malignancies, namely, an impaired respiratory rate of the tumor tissue, a partial failure of the Pasteur effect, and an excessive rate of aerobic glycolysis, i.e., the formation of lactic acid from glucose in the presence of oxygen. Subsequent studies indicated, however, that these notions were neither characteristic nor unique to malignant tumors (e.g., aerobic glycolysis is also found in the renal medulla, in the retina, in leukocytes, and in other phagocytic cells). Oxygen consumption rates of tumors in vivo are intermediate between normal tissues with low metabolic rates and normal tissues with quite high activities (Fig. 2). The same holds true for the oxygen utilization; i.e., O2 extraction is not impaired and respiratory function of cancer cells is not deficient (see Table 3). For comprehensive studies on the respiration rate of human tumor tissues ex vivo see the reports of Aisenberg (72), Alvarez et al. (73), Constable et al. (74), Macbeth and Bekesi (75), and Shapot (76).

Tumor Tissue Oxygenation

As already mentioned, tissue oxygenation is one of those factors which define the cellular microenvironment and which are known to be able to modulate the sensitivity of cancer cells to certain nonsurgical treatment modalities. As a rule, tissue oxygenation is the resultant of the oxygen availability (nutritive blood flow x arterial O2 concentration) and the actual respiration rate of the cells. The arterial O2 concentration is mostly determined by the O2 partial pressure of the arterial blood, the shape of the O2 dissociation curve, the hemoglobin concentration, and the temperature of the blood (25). Release of O2 from the RBC into the tissues is mostly dependent on the shape of the O2 dissociation curve (which can be shifted through changes of pH, CO2 partial pressure, and temperature etc.), the fluidity of RBC and the O2 partial pressure (pO2) gradient between the blood and the surrounding tissue. Diffusional flux (m) within the tissue is directly proportional to the difference in O2 partial pressures (ΔP), to Krogh's diffusion coefficient (K), and the exchange area (A) and inversely proportional to the diffusion distance (x).

\[ m = K \cdot A \cdot ΔP/Δx \]  
(Fick's first law of diffusion)  

Krogh's diffusion constant is defined as

\[ K = D \cdot α \]  
(ml O2-cm⁻¹-min⁻¹-atm⁻¹)  

and has been measured for tumor tissue within the temperature range of 20–40°C. It has been shown to correspond to values of normal tissue with similar water content (77, 78; D = O2 diffusion coefficient, α = O2 solubility coefficient).

In normal tissues the oxygen supply meets the requirements of the cells. This is accomplished by modulating tissue blood flow and/or by changing the O2 utilization (or O2 extraction) in accordance with alterations in physiological conditions.

\[ \text{O2 utilization} = \frac{\text{O2 consumption}}{\text{O2 availability}} \]  

or

\[ \text{O2 utilization} = \frac{\text{Arteriovenous O2 concentration difference}}{\text{Arterial O2 concentration}} \]  

In poorly perfused tumors, modulations of both mechanisms are rather limited. For this reason, O2 deficiency is a common feature in those malignancies.

Besides mathematical evaluations of the pO2 distribution in tissues, polarographic and cryospectrophotometric microtechniques have been used to gain an insight into the oxygenation of tissue microareas. Utilizing O2-sensitive invasive microelectrode techniques, the pO2 distribution has been measured in normal tissues and tumors of patients. In contrast, the spectro-
Table 3: Oxygen utilization (O2 extraction ratio, O2 extraction fraction) of human tumors and normal tissues

<table>
<thead>
<tr>
<th>Tissue</th>
<th>O2 utilization (v/v)</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astrocytoma</td>
<td>0.03–0.52*</td>
<td>28, 33, 37, 39</td>
</tr>
<tr>
<td>Brain metastases</td>
<td>0.17–0.55*</td>
<td>28, 33, 37, 39</td>
</tr>
<tr>
<td>Hodgkin’s lymphomas (spleen)</td>
<td>0.10</td>
<td>71</td>
</tr>
<tr>
<td>Breast cancers</td>
<td>0.10–0.35*</td>
<td>27, 40</td>
</tr>
<tr>
<td>Brain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Whole</td>
<td>0.35–0.47*</td>
<td>27</td>
</tr>
<tr>
<td>Gray matter</td>
<td>0.30–0.35</td>
<td>25</td>
</tr>
<tr>
<td>White matter</td>
<td>0.30–0.68*</td>
<td>33*</td>
</tr>
<tr>
<td>Gray matter</td>
<td>0.37–0.67*</td>
<td>28, 37, 39, 56*</td>
</tr>
<tr>
<td>White matter</td>
<td>0.45–0.50</td>
<td></td>
</tr>
<tr>
<td>0.25–0.35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skeletal muscle</td>
<td>0.45–0.75</td>
<td></td>
</tr>
<tr>
<td>Spleen</td>
<td>0.05</td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>0.08–0.10</td>
<td></td>
</tr>
<tr>
<td>Heart</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At rest</td>
<td>0.50–0.75</td>
<td>25</td>
</tr>
<tr>
<td>Strenuous exercise</td>
<td>0.85</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>0.20–0.25</td>
<td></td>
</tr>
<tr>
<td>Portal vein</td>
<td>0.20</td>
<td></td>
</tr>
<tr>
<td>Hepatic artery</td>
<td>0.40–0.50</td>
<td></td>
</tr>
<tr>
<td>Carotid body</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>Breast (postmenopausal)</td>
<td>0.50–0.75*</td>
<td>40</td>
</tr>
</tbody>
</table>

* PET study (13N2).
* Oxygen utilizations are most probably overestimations since these studies did not correct for intravascular activity.

Photometric microtechnique enables the measurement of the HbO2 of individual RBC within microvessels (<12 μm) of cryobiopsies taken from patient malignancies and from the normal tissue of origin.

Oxygen Partial Pressure Distribution. Oxygen partial pressure distributions for isotransplanted tumors have been described in detail (11, 79, 80). In general, as a result of a compromised and anisotropic microcirculation, most of these malignancies reveal hypoxic and anoxic tissue areas which are heterogeneously distributed within the tumor mass. In poorly perfused human tumor xenografts, hypoxic (pO2 < normal) and anoxic (pO2 = 0 mm Hg) regions were already present at early growth stages and expanded with tumor growth (22, 23). In contrast, s.c. human tumor xenografts with high perfusion rates have tissue oxygénations comparable to those of most normal organs. This is most probably due to an adequate vascularization of the latter tumors (23). Only at larger sizes did these tumors "outgrow" their vasculature and hypoxic/anoxic tissue areas develop.

When size-dependent changes in the O2 partial pressure distribution and in the tumor energy status of a murine fibrosarcoma (FSaII) and a mammary adenocarcinoma (MCA4V) were investigated in vivo using conscious animals and biologically relevant tumor sizes, a progressive loss of PCr and NTP with increasing PME, and PDE signals together with a decline of the median (or mean) tissue pO2 values was observed during growth (81, 82). When the mean pO2 values were plotted against the NTP/PCr, PME/PCr, and PDE/PCr ratios for tumor groups of similar mean volumes, a highly significant positive correlation was observed. From these results, it was concluded that 31P NMR spectroscopy can be used to indirectly evaluate tumor tissue oxygénation. Furthermore, the close correlation between tumor tissue oxygen distribution and bioenergetics suggests that the microcirculation of these murine tumors yields an O2-limited energy metabolism.

Frequency distributions of measured pO2 values (pO2 histograms) for various normal human tissues are given in Fig. 3. As expected, there is a scattering of the tissue pO2 values between 1 mm Hg and values typical for arterial blood (80–100 mm Hg). The median pO2 values for some normal tissues are given in Table 4. Whereas in these normal tissues the medians range from 24 to 66 mm Hg, in malignancies the respective values in all malignancies analyzed thus far are ≤20 mm Hg. On comparison of the pO2 histograms of normal tissues with those of squamous cell carcinomas, breast cancers, or stomach cancers (see Fig. 4) there is clear evidence that in tumors there is a distinct shift of the distribution curve to the left; on the average, the mean pO2 values are lower in malignancies than in surrounding normal tissues (see Table 5), there is less scattering of the pO2 values due to lacking high pO2 values, and there is an accumulation of pO2 values in the lower pO2 classes indicating tissue hypoxia and thus reduced radiosensitivity in tumors.
BLOOD FLOW AND METABOLISM OF HUMAN TUMORS

Fig. 4. pO2 histograms for squamous cell carcinomas (A), breast cancers (B), and a gastric adenocarcinoma (C). Pooled data are given for the different tumor types (for references see Table 4).

Table 5 Comparison between the mean pO2 values in normal tissues and in human malignancies

<table>
<thead>
<tr>
<th>Tumor type</th>
<th>pO2 (normal tissue)</th>
<th>pO2 (tumor)</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervix cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 0</td>
<td>1.6</td>
<td>91</td>
<td></td>
</tr>
<tr>
<td>Stage 1</td>
<td>2.4</td>
<td>91</td>
<td></td>
</tr>
<tr>
<td>Stage 2</td>
<td>3.2</td>
<td>101</td>
<td></td>
</tr>
<tr>
<td>Stage 2</td>
<td>1.4-1.8</td>
<td>101</td>
<td></td>
</tr>
<tr>
<td>Squamous cell carcinomas</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.7</td>
<td>105</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.4</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.4</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6.3</td>
<td>107</td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>1.4</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.0</td>
<td>105</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.4</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.4</td>
<td>107</td>
<td></td>
</tr>
<tr>
<td>Melanomas</td>
<td>6.3-6.7</td>
<td>86, 106, 107</td>
<td></td>
</tr>
<tr>
<td>Soft tissue sarcomas</td>
<td>2.8</td>
<td>107</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6.3</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>Malignant lymphomas</td>
<td>1.5</td>
<td>105</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.2</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>Adenocarcinomas</td>
<td>7.1</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>Basal cell epitheliomas</td>
<td>5.6</td>
<td>107</td>
<td></td>
</tr>
</tbody>
</table>

* Ratio of mean O2 tension in normal tissue to mean O2 tension in tumors.

On the basis of distributions such as those presented in Fig. 4 one can estimate the fraction of tumor cells that have reduced radiation sensitivity induced by their poor oxygenation status (i.e., the radiobiologically hypoxic cell fraction). Specifically, cells in environments with pO2 values below those found in venous blood will have less than maximum radiation sensitivity.

and less than 3–4 mm Hg will have a 2-fold or greater reduction in sensitivity compared to well oxygenated tissues (see Fig. 5).

The changes in the tissue pO2 distribution of cervix cancers at different growth stages are shown in Fig. 6. Whereas in the normal cervical mucosa the median pO2 is 36 mm Hg (7), in cervical cancers it drops to 20 mm Hg at stage 0, to 13 mm Hg at stage I, and to 5 mm Hg at stage II (91, 101). Concurrent with this lowering of the median pO2 values, the pO2 histogram is tilted to the left and limited in variability compared to the normal cervix mucosa. These data are indicative of an inadequate O2 supply to the tissue, most probably due to a restriction of the microcirculation and thus of the O2 availability to the cancer cells in vivo. As the tumors increase in size, this situation is significantly aggravated. Besides intratumor heterogeneities, there is a marked tumor-to-tumor variability, even if tumors of the same size, at the same growth site, and of the same cell line are compared. Evaluations of the vascular density in carcinomas of the uterine cervix are in accordance with the pO2 data reported (91, 108, 109). In these studies the mean intercapillary distances (304 ± 30 μm) either were relatively independent of the clinical stage and histological grade (108) or revealed a

Fig. 5. Relative radiosensitivity as a function of O2 partial pressure (pO2) in the cellular environment (schematic representation). Range of pO2 values usually found in blood, normal tissues, and malignant tissues (shaded bars) and O2 partial pressure at which the sensitizing effect is half-maximal (3–4 mm Hg) are indicated.

Fig. 6. pO2 distribution in normal cervix mucosa (A) and in cervix cancers at different clinical stages. B, stage 0; C, stage I; D, stage II [poole | cancerres.aacrjournals.org on November 12, 2012 Copyright © 1989 American Association for Cancer Research.

6455

Downloaded from cancerres.aacrjournals.org on November 12, 2012 Copyright © 1989 American Association for Cancer Research.
Oxygen saturation of malignant tumors is important in understanding tumor physiology and treatment outcomes. Over 60 years ago, Warburg (70) studied the glucose turnover using tumor slices incubated aerobically and noted high rates of lactic acid production. From these experiments and others, an attitude regarding the high rate of aerobic glycolysis and lactate release became a biochemical “hallmark” of malignancies. Since that time, further insight into this aspect of tumor energy metabolism has been added including three different mechanisms of glucose turnover: glucose oxidation; aerobic glycolysis (breakdown of glucose to lactic acid in the presence of oxygen); and anaerobic glycolysis (breakdown of glucose to lactic acid in the absence of oxygen).

The investigation of Warburg’s hypothesis under in vivo conditions was permitted by the development of “tissue-isolated” tumor preparations using kidney, ovary, testis, or an inguinal fat pedicle as implantation sites (122–126). In these studies, blood flow, glucose uptake, and lactate production of...
isotransplanted rat tumors were measured. Recently, the inguinal implantation site was used to study the turnover of glucose and other substrates like ketone bodies and amino acids (127–130).

As a rule, in these studies the glucose uptake rate was directly proportional to the glucose availability; i.e., the glucose consumption was governed by tumor blood flow assuming constant arterial glucose concentrations during normoglycemia. These in vivo studies further revealed a deprivation of nutrients and an insufficient removal of metabolic waste products, predominantly lactic acid, causing tissue acidosis. Because blood flow through most of the isotransplanted tumors investigated was already compromised in small tumors and inadequacy in flow aggravated during tumor growth, weight-adjusted glucose uptake rates declined with enlarging tumor volume.

From studies using xenografted human tumors there is again evidence that the substrate supply and not the metabolic demand of the tumor cells limits the glucose uptake. This is probably due to the fact that even in high-flow tumors supply rates are not high enough to meet the demand of the cells. This finding infers steep concentration gradients for glucose in the extravascular space of human tumor xenografts (23, 131, 132). The capacity to consume glucose varied 4-fold between the different human cell lines. Due to an anisotropic flow distribution in individual tumors of one cell line, a heterogeneous glucose uptake rate must be expected within the tumor mass.

As a rule, the amount of lactate released was linearly related to the amount of glucose consumed. Assuming steady state conditions and glucose to be the only substrate source of lactate, the glycolytic rate can be determined as the ratio of the lactate release and the glucose uptake. With this assumption, it was found that depending on the human cell line investigated, 40–85% of the glucose taken up can be released as lactate. These data represent average rates with substantially lower rates in small tumors and higher proportions in bulky malignancies (23, 132). In the xenograft studies, pH values in the tumor venous blood were close to arterial levels in tumors with high flow rates, indicating a high glucose demand of malignancies with growth, indicating a high glucose demand of malignancies with grades III and IV.

Several investigators attempted to characterize the glucose utilization of brain tumors (see Table 6). Di Chiro et al. (135) found a strong correlation between the glucose consumption rate and the grade of astrocytomas, with visual “hot spots” present in all high-grade tumors (grades III and IV) and only in a few low-grade lesions (grades I and II). The analysis of 100 patients revealed an average glucose uptake rate of grade I and II astrocytomas of 0.21 ± 0.10 μmol/g/min, compared to 0.30 ± 0.15 μmol/g/min in cases of grade III and 0.41 ± 0.20 μmol/g/min in verified cases of grade IV astrocytomas. However, for individual diagnosis, the absolute metabolic rate was found to be less useful than the visual appearance of the PET scan. In addition, these investigators found a regional depression of the glucose uptake in peritumoral regions. Seventeen patients with intracranial meningeomas were studied by Di Chiro et al. (134). In this investigation, the authors showed that the glucose-metabolic rates correlated with the tumor growth rate. They concluded that the glucose utilization rate appears to be at least as reliable as histological classification and other proposed criteria for predicting the therapeutic response and recurrence of intracranial meningeomas.

Similar correlations were found for the amino acid uptake of astrocytomas and the histological grading. In grade IV tumors the L-[13C]methionine uptake was twice the value found in grade II lesions (149). Using metabolic imaging of human soft tissue sarcomas by PET, again a good correlation was found between the glucose uptake rate and the histopathological grading [glucose uptake rate was increased 4-fold in grade III tumors compared to grade I malignancies (138)].

Patronas et al. (137) used the PET technique to evaluate a group of patients with proved high-grade gliomas to see if the data obtained had any prognostic value. In this study, radiation-induced tumor necrosis was associated with a reduced glucose utilization in the lesion, whereas in recurrent gliomas the glucose uptake was elevated. Similar differences were reported by Di Chiro et al. (134). These authors found a 2-fold higher glucose uptake rate in recurrent and/or regrowing meningiomas than in tumors that did not recur. On the average, glucose uptake of brain tumors was not significantly different from that obtained for the normal cerebral cortex (see Table 6). In lung cancers and soft tissue sarcomas, glucose utilization was 3–6 fold higher than in the normal tissues at the site of tumor growth, indicating a high glucose demand of malignancies with

### Table 6 Glucose uptake rates (V_Wu) of human malignancies and of normal tissues (PET-derived data)

<table>
<thead>
<tr>
<th>Tissue</th>
<th>V_Wu (μmol/g/min)</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meningiomas</td>
<td>0.03–0.43</td>
<td>134</td>
</tr>
<tr>
<td>Astrocytomas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grades I–II</td>
<td>0.14–0.43</td>
<td>135, 136</td>
</tr>
<tr>
<td>Grades III–IV</td>
<td>0.12–0.88</td>
<td>137, 39</td>
</tr>
<tr>
<td>Soft tissue sarcomas</td>
<td>0.15–0.51</td>
<td>138</td>
</tr>
<tr>
<td>Lung cancers</td>
<td>0.11</td>
<td>139</td>
</tr>
<tr>
<td>Squamous cell carcinomas</td>
<td>0.24*</td>
<td>133</td>
</tr>
<tr>
<td>Whole brain</td>
<td>0.30–0.40</td>
<td>140</td>
</tr>
<tr>
<td>Gray matter</td>
<td>0.25–0.51</td>
<td>141</td>
</tr>
<tr>
<td>White matter</td>
<td>0.08–0.28</td>
<td>142</td>
</tr>
<tr>
<td>Brain stem</td>
<td>0.18–0.28</td>
<td>143</td>
</tr>
<tr>
<td>Spinal cord</td>
<td>0.09</td>
<td>144–147</td>
</tr>
<tr>
<td>Lung parenchyma</td>
<td>0.017</td>
<td>139</td>
</tr>
<tr>
<td>Myocardium</td>
<td>0.6–1.5</td>
<td>148</td>
</tr>
<tr>
<td>Skeletal muscle (at rest)</td>
<td>0.05–0.07*</td>
<td></td>
</tr>
</tbody>
</table>

* Calculated uptake rate considering a mean blood flow of head and neck cancers of 0.136 ml/g/min (51).

* Uptake rate for quadriceps muscle in rodents (F. Kallinowski et al., unpublished results.).
an increase in the nonoxidative glucose metabolism (tumor cells are "avid" glucose consumers).

**Other Nutrients**

Sauer et al. (129) have suggested that ketone bodies may be important fuels for tumor growth in vivo in fasted and semi-fasted animals. They found that both acetocetate and β-hydroxybutyrate were utilized by transplanted rat tumors in vivo and that the uptake rates were directly proportional to the respective availabilities. Interestingly, in these experiments lactate was also utilized when arterial lactate levels exceeded 3 mM.

Ketone body metabolism has also been shown to be a qualitatively important feature in human breast cancer xenografts (132). Here again, the uptake rates were linearly related to the respective availabilities. The mean uptake of β-hydroxybutyrate was 3.5 nmol/g/min and that of acetocetate was 2.6 nmol/g/min. At similar availabilities the uptake rates of the ketone bodies were comparable for the isografted rodent tumors and the xenografted human breast carcinomas. In the human tumor xenografts the β-hydroxybutyrate/acetocetate ratio in the tumor venous blood rose with decreasing tumor blood flow (which occurred with increasing tumor volume) indicating a heavy reliance on anaerobic metabolic pathways, at advanced growth stages (132).

The first and only direct demonstration of ketone body uptake by human tumors in vivo was published by Richtsmeier et al. (133). In this study arteriovenous concentration differences for β-hydroxybutyrate and acetocetate in head and neck cancers were measured. The respective mean concentration differences were 0.07 mM for β-hydroxybutyrate, and 0.09 mM for acetocetate. All tumors studied took up the ketone bodies but in varying amounts indicating metabolic heterogeneity between the tumors. The utilization was 14% for β-hydroxybutyrate and 38% for acetocetate. Assuming a mean blood flow rate of head and neck cancers of 0.136 ml/g/min (51) the respective uptake rates were 9.5 nmol/g/min for β-hydroxybutyrate and 12.2 nmol/g/min for acetocetate. Comparable uptake rates were measured. The respective mean concentration differences (132). In this study arteriovenous concentration differences for β-hydroxybutyrate and acetocetate in head and neck cancers were measured. The respective mean concentration differences were 0.07 mM for β-hydroxybutyrate, and 0.09 mM for acetocetate. All tumors studied took up the ketone bodies but in varying amounts indicating metabolic heterogeneity between the tumors. The utilization was 14% for β-hydroxybutyrate and 38% for acetocetate. Assuming a mean blood flow rate of head and neck cancers of 0.136 ml/g/min (51) the respective uptake rates were 9.5 nmol/g/min for β-hydroxybutyrate and 12.2 nmol/g/min for acetocetate. Comparable uptake rates were found for xenografted human breast cancers (132). Ketone body uptake by human tumors appears to be proportional to the availability. It seems reasonable to assume that the carbons of the ketone bodies are used for both energy metabolism and macromolecule synthesis in the squamous cell carcinomas studied.

Considerable evidence has accumulated indicating L-glutamine as a major substrate for the energy metabolism of rapidly growing tumor cells in vitro. Since oxygen is necessary for the oxidative breakdown of glutamine to pyruvate, an adequate oxygen supply to cancer cells during glutaminolysis is a prerequisite. Under in vivo conditions, however, hypoxia is a common feature in poorly vascularized malignancies. Considering this oxygen supply pattern, it may be postulated that glutamine can be a significant substrate for cancer cells only in the immediate neighborhood of nutritious tumor vessels and that due to the heterogeneous oxygenation of human tumors in vivo, glutaminolysis may also be heterogeneously distributed within the tumor mass (for a detailed discussion see Ref. 150).

**Metabolic Imaging of Human Tumors on a Microscopic Level**

A method has been developed for metabolic imaging on a microscopic level in tumor tissues (151). This technique makes possible the determination of the spatial distribution of glucose, lactate, and ATP in absolute terms at similar locations within tumors. The substrate distributions are registered using bioluminescence reactions in serial cryostat sections from tissue biopsies. The light emission is measured directly by a special imaging photon counting system allowing on-line image analysis. Thus far, this technique has been applied to human breast cancer xenografts and to primary adenocarcinomas of the rectum.

Preliminary data obtained indicate that heterogeneities in the substrate distributions measured are much more pronounced in tumors than in normal tissue (e.g., resting skeletal muscle). There was no obvious correlation between glucose, lactate, and ATP levels measured at similar locations within the tissue (for further details see Ref. 151).

Biopsies were taken from human breast cancers xenografted into immunodeficient rats (132) and from untreated rectal carcinomas with special, cooled tongs and immediately dropped into liquid nitrogen (within 1 s). For measurement of the distributions of ATP, glucose, and lactate levels in these biopsies, the frozen tissue samples were cut into 20-μm sections at −25°C. The cryostat sections were then placed on coverglasses, freeze-dried, and except for the glucose measurements, heat inactivated. Afterwards, these sections were covered with 60-μm cryostat sections of a frozen cocktail of enzymes that link the substrate of interest to the bioluminescence of luciferase. Upon thawing the sandwich of sections, the enzymes diffused into the tissue section, thus initiating the bioluminescence reaction (phoemission) which was registered by film exposure. The absorbance of the exposed film was then evaluated by microdensitometry and image analysis.

The spatial distribution of ATP in a section through a human breast cancer xenograft is shown in Fig. 9B. Although the data are plotted in relative units, they clearly illustrate pronounced heterogeneities in the ATP levels within these tumors. Micro-regions with very low ATP concentrations (yellow areas) are randomly distributed between areas with higher concentrations (green and red areas) in this section. The shape of the ATP distribution was highly reproducible between adjacent tissue sections. In general, the average ATP concentrations in those tumors were substantially lower (approximately 1 mM) than in normal skeletal muscle (as shown in Fig. 9A). ATP concentrations in skeletal muscle were not only distinctly higher (approximately 5–6 mM) but also more evenly distributed, although some heterogeneities were also present even in this normal tissue.

**Tumor pH**

Rapidly growing tumor cells usually have a high metabolic rate which often cannot be adequately met by the nutrient supply under in vivo conditions. Carbon used for energy metabolism is derived from several sources (e.g., glucose, amino and free fatty acids, ketone bodies, and even lactate when supplied in excess). During aerobic and/or anaerobic glycolysis, glutaminolysis, and ATP hydrolysis, hydrogen ions are formed which are actively transported outside the cell. Via the interstitial space the H+ ions finally reach the blood vessels and are removed from the tissue thereafter by convective transport. If a high glycolytic rate and a high lactic acid production coincide with an insufficient drainage by convective and/or diffusive transport, H+ ions accumulate in the respective tissue. As a result, pH is shifted to more acidic values, especially in bulky and/or low-flow tumors (23). If microcirculatory inadequacy is combined with functional heterogeneity, pH variability becomes
a common feature both within a tumor and between tumors. A basic prerequisite for the development of acidosis, however, is that glucose is available to hypoxic cancer cells. Since the diffusion distance for glucose is larger than that for O₂, this prerequisite is usually met. In a recent paper, Kalininowski et al. (150) have estimated that this holds true for xenografted human breast cancers; i.e., hypoxic tumor cells far away from the supplying vessel can still cleave glucose to lactic acid. Therefore, it is not surprising that inverse correlations between the lactic acid content and the interstitial pH have been found in tumors (152–154).

Much work has been done on the effect of acidosis upon cells in tissue culture and in animal tumor systems (for a review see Ref. 12). Low pH has been shown to inhibit cell proliferation, DNA synthesis, and glycolysis. A shift of cells to G₁ and G₀ in the cell cycle has been described. In addition, a loss in transplantability and an enhancement of metastasis formation have been found under experimental conditions. Acidosis can decrease the radiosensitivity of mammalian cells, modulate the cytotoxicity of certain anticancer drugs, influence the thermal radiosensitization, enhance the cell killing effect of heat, and inhibit the development of thermotolerance. Modification of baseline pH in tumors is possible by administration of glucose and upon tumor treatment, especially hyperthermia at temperatures above 42°C and treatment times exceeding 15 min.

The pH of human tumor tissues has been measured by a variety of techniques. The most traditional technique is the use of pH-sensitive electrodes with tip diameters ranging from 0.5 μm to 2 mm. This method has the disadvantage that it is invasive and, therefore, that large electrodes can affect tumor microcirculation and thus the cellular metabolic microenvironment. Whereas the microelectrode technique allows for the description of the pH distribution in microareas of the tumors, miniaturized electrodes can register integrated pH values only from a relatively large tumor volume. Thus far, there are no significant differences between the average tumor pH values obtained with micro- or with minielectrodes. Since these measurements are based on the potentiometric technique, in the following pH data obtained with electrodes are designated as pHₑ 호텔. What is actually measured by electrodes is generally accepted to represent the hydrogen ion activity* rather than the H⁺ concentration. pH values obtained with microelectrode measurements are a composite pH with contributions from the interstitial and intravascular pH expected to be at least 50% (66). In contrast to the electrode measurements, pHₑᵢ and pHₑᵣ are largely dependent upon the pH of the intracellular space.

\[ \text{pHₑᵢ} \]

Compared to the values in normal tissues, tumor pH distributions obtained in animal studies are generally shifted to more acidic values (ΔpH = 0.3–0.5 unit). pH values in spontaneous rat tumors were not significantly different from those found in isoinfected malignancies (7). There is a trend towards more acidic pH values as the tumor mass enlarges with a broad range of pH values determined. This wide range most probably is due to intratumor heterogeneities, to tumor-to-tumor variations, and possibly to variations between different tumor pathologies (for reviews, see Refs. 7 and 12). The wide range of pH values that have been determined in human tumors using electrode measurements is shown in Fig. 9. Pooled data are given for primary brain tumors and brain metastases (155), malignant melanomas (156, 157), sarcomas (157, 158), breast cancer (12, 159), squamous cell carcinomas, and adenocarcinomas (150). The measurements of Inch (160), Meyer et al. (161), Millet (162), Naeslund and Swenson (163), and Okunoff (164) cannot be regarded as being relevant since they are “burdened” with methodological problems.

Whereas most human tumors exhibit pH values between 6.15 and 7.40 (the latter value representing the mean pH of arterial

\[ \mu_i = \mu_i^0 + RT \ln a_i \]

where \( R \) is the gas constant (per mol), \( T \) is the absolute temperature, \( \mu_i \) is the chemical potential of the component, and \( \mu_i^0 \) is the chemical potential in the standard state.
In addition to human tumor pH values, a summary of normal tissue pH values is given in Table 7. Normal human brain tissue pH values are given in Table 10. Normal human brain tissue pH values are given in Table 10. Normal human brain tissue pH values are given in Table 10. Normal human brain tissue pH values are given in Table 10. Normal human brain tissue pH values are given in Table 10. Normal human brain tissue pH values are given in Table 10.

In human tumor, pH values measured with pH-sensitive electrodes (pH mem) in human tumors (160), and in normal tissues (161). Arrowheads, respective mean values; numbers in parentheses, number of tumors investigated. The pH data obtained in human tumors and melanomas were significantly lower than those in normal cerebral gray matter and in the skin, respectively (P < 0.001).

Recent investigations have revealed generally more alkaline pH values in human tumors than in normal gray or white matter (see Table 7). As discussed by Junck et al. (181), differences in the size of the interstitial spaces of tumors and normal brain tissue might be responsible for the relative alkalinity of the tumors. This hypothesis, however, must be tested in further experiments (for a detailed discussion see "pH NMR").

pH NMR

Magnetic resonance spectroscopy of human tumors and its potential in vivo clinical applications have been reviewed recently (182, 183). 31P nuclear magnetic resonance spectroscopy is able to provide important biochemical information in living tissues, especially of high-energy phosphate and (membrane) phospholipid metabolism. Because in vivo 31P NMR observes the unperturbed biochemical processes at the molecular level, the effect of cancer treatments would most likely be revealed in the spectra earlier than other traditional techniques, such as biopsies or other laboratory analyses. In addition, because the nuclear magnetic resonance spectroscopy technique is noninvasive, nonperturbing, and painless, it allows the patient to be repeatedly monitored throughout the course of treatments (184).

In vivo 31P NMR spectroscopy has been used to monitor the energy metabolism of human tumors since 1983 (185). From the studies available, information is provided that may be useful for diagnostic informations or beneficial in clinical treatment of cancer. Furthermore, there are hints that serial monitoring of tumor response can assist in optimizing the timing treatments. If 31P NMR spectra from normal tissues (e.g., skeletal muscle or parenchymal breast) are compared with their malignant counterparts, abnormally high concentrations of PME, phosphodiester, and P, and low PCr levels are characteristic for the latter. Unlike many grafted murine tumors and human tumor xenografts, human malignancies have relatively lower P, levels and somewhat higher NTP signals. This may be an indication that the hypoxic cell fraction in human neoplasms is smaller than in some rapidly growing rodent tumors. As a rule, in malignant tumors the NTP/P, ratio is lower compared with that in normal or uninvolved tissue from the same patient. In tumors of mesenchymal origin and in brain tumors, the PCR/NTP and the NTP/P, ratios are both reduced compared to muscle and brain, respectively. This is consistent
with a more anaerobic tumor metabolism (183) and a depletion of energy stores.

pH values as measured by $^{31}$P nuclear magnetic resonance ($^{31}$P NMR) spectroscopy are best considered a composite pH with contributions from intracellular pH expected to be at least 85% of the total (186). In general, the PCR to P, chemical shift is used to estimate the apparent intracellular pH in the tissues of interest (187). In the absence of a sharp PCR resonance, the $\alpha$-NTP resonance which is also pH insensitive can serve as a chemical shift reference, enabling pH determinations of similar accuracy.

Pooled pH data obtained from $^{31}$P NMR measurements are shown in Fig. 11. Values are given for various sarcomas (185, 188–190), squamous cell carcinomas (189–192), breast cancer (193, 194), brain tumors (191, 195–199), non-Hodgkin’s lymphomas (184, 197, 200), miscellaneous malignancies (201), skeletal muscle (185, 188–190, 201–206), brain (191, 195, 197, 199, 201, 207, 208), liver (191, 209), heart (210), erythrocytes (211, 212), and lymphocytes (213). From the data available thus far there is clear evidence that the pHNMR values for brain tumors are significantly higher than those obtained for normal brain structures. This finding is in accordance with pH data derived from PET studies. Furthermore, pHNMR values in sarcomas tend to be somewhat higher than those for resting skeletal muscle. pH differences seen between normal tissues (skeletal muscle, brain) and malignancies (brain tumors, sarcomas) are on the order of 0.1 pH unit. The exact mechanisms causing these (unexpected) pH differences are unknown at present.

As a rule, intracellular pH is normally maintained above the equilibrium pH by active net proton transport into the extracellular space (214). According to the report of Arnold et al. (195) the more alkaline pH in brain tumors and sarcomas compared to the respective normal tissues may be due to an enhanced active $\text{H}^+$ transport into the extracellular compartment, an increased cellular buffering capacity, a net change in cellular strong organic acid concentration (e.g., lactic acid), and/or an increase in the equilibrium potential for $\text{H}^+$ ions.

At the moment the most convincing theory explaining the progressive alkalinization of (certain) tumor cells is based on a loss of membrane potential secondary to a redistribution of $\text{K}^+$ and other ions. As the membrane potential becomes more positive than the equilibrium potential for $\text{H}^+$ ions (approximately $-24 \text{ mV}$, see Ref. 195), this mechanism can result in a passive hydrogen ion efflux from the cell yielding intracellular alkalinization.

In a very recent study, Ng et al. (192) have observed normal and alkaline pH values in 34 of 35 superficial tumors examined, thus confirming earlier results on brain tumors and sarcomas. In the latter investigation, pH ranged from 6.90 to 7.60 (mean pH, 7.22) in squamous cell carcinomas of the head and neck (lymph nodes), from 7.21 to 7.60 (mean pH, 7.34) in non-Hodgkin’s lymphomas, from 7.09 to 7.67 (mean pH, 7.36) in Hodgkin’s lymphomas, and from 7.40 to 7.70 (mean pH, 7.57) in breast cancer.

Acknowledgments

The authors would like to thank Drs. R. K. Jain and J. Folkman for their encouragement to write this review. Furthermore, we would like to acknowledge the skillful assistance of Claudia Zanker in typing this manuscript.

REFERENCES

49. Nystrom, C., Forssman, L., and Roos, B. Myometrial blood flow studies in


45. Taylor, I., Bennett, R., and Sherriff, S. The blood supply of colorectal liver

blood flow and oxygen utilisation in patients with unresectable intrahepatic

50. Waterman, F. M., Nerlinger, R. E., Moynan, D. J., and Leeper, D. B.

45. Taylor, I., Bennett, R., and Sherriff, S. The blood supply of colorectal liver


45. Taylor, I., Bennett, R., and Sherriff, S. The blood supply of colorectal liver

blood flow in patients with tumors of the liver. Gastroenterology, 44: 736-
739, 1963.


1986.


1986.


1986.
BLOOD FLOW AND METABOLISM OF HUMAN TUMORS


bolic changes in cerebral gliomas within hours of treatment with intra-
arterial BCNU demonstrated by phosphorus magnetic resonance spectro-

196. den Hollander, J. A., and Luyton, P. R. Image-guided localized 1H and 31P

197. Segebarth, C. M., Baleriaux, D. F., Arnold, D. L., Luyton, P. R., and den
Hollander, J. A. MR image-guided P-31 MR spectroscopy in the evaluation

198. Hubesch, B., Sappeg-Mariner, D., Roth, K., Sanuki, E., Hodes, J. E.,
Matson, G. B., and Weiner, M. W. Improved ISIS for studies of human
brain and brain tumors. In: Proceedings of the 7th Annual Meeting of the
Society for Magnetic Resonance Medicine, San Francisco, Vol. 1, p. 348,

199. Cadoux-Hudson, T., Blackledge, M. J., Rajagopalan, B., Taylor, D. J., and
Radda, G. K. Measurement of phosphorus metabolites in patients with
intracranial tumors. In: Proceedings of the 7th Annual Meeting of the
Society for Magnetic Resonance Medicine, San Francisco, Vol. 2, p. 614,

200. Ng, T. C., Vijayakumar, S., Majors, A. W., Baldwin, N. J., Taylor, M. E.,
Thomas, F. J., Saxton, J. P., Meany, T. F., Grundfest, S., and Tubbs, R.
Examination of 31-P MRS metabolites and intracellular pH in 25 human

201. Ng, T. C., Majors, A. W., and Meany, T. F. In vivo MR spectroscopy of
human subjects with a 1.4-T whole body MR imager. Radiology, 158: 517–
520, 1986.

Magnetic resonance spectroscopy of the musculoskeletal system. Radiol.

203. Itoh, M., Kawahara, T., Yohikawa, K., Jogi, K., Ito, M., Yamai, S., Iriuchi,
N., and Maki, T. Measurement of in vivo dynamic metabolism of the athletes
and overtraining runner by 31P-NMR. In: Proceedings of the 6th Annual
Meeting of the Society for Magnetic Resonance Medicine, New York, Vol.

204. Gross, B., Kensora, T. G., Glasberg, M. R., Welch, K. M. A., and Smith,
M. B. Early intracellular acidosis during exercise in sensory neuropathy: 31-
P NMR spectroscopy study. In: Proceedings of the 6th Annual Meeting of
the Society for Magnetic Resonance Medicine, New York, Vol. 2, p. 1036,
1987.

pH of human muscle by 1H NMR. In: Proceedings of the 7th Annual

206. Wilson, J. R., McCuly, K. K., Mancini, D. M., Boden, B., and Chance, B.
Relationship of muscular fatigue to pH and diprotonated P in humans: A

207. Levine, S. R., Welch, K. M. A., Helpert, J. A., Bruce, R., Ewing, J. R.,
Kensora, T., and Smith, M. B. Cerebral cortical phosphate metabolism and
pH in patients with multiple subcortical infarcts: a controlled study with
Meeting of the Society for Magnetic Resonance Medicine, New York, Vol.

208. Jensen, K. E., Thomsen, C., and Henriksen, O. In vivo measurement of
intracellular pH in human brain during different tensions of carbon dioxide

209. Segebarth, C., Grivegnee, A., Luyton, P. R., and den Hollander, J. A. 31P
MR spectroscopy of the human liver. Assessment of fructose metabolism.
In: Proceedings of the 6th Annual Meeting of the Society for Magnetic

210. Vermeulen, J. W. A. H., Luyton, P. R., van der Heijden, J. I., and den
Hollander, J. A. Uncovering the P signal in the in vivo 31P NMR spectrum
of the human heart. In: Proceedings of the 7th Annual Meeting of the
Society for Magnetic Resonance Medicine, San Francisco, Vol. 2, p. 833,

pH in human and experimental hypertension. Proc. Natl. Acad. Sci. USA,

212. Petersen, A., Jacobsen, J. P., and Heder, M. 31P NMR measurements of
intracellular pH in erythrocytes: direct comparison with measurements using
freeze-thaw and investigation into the influence of ionic strength and Mg2+.

213. Iles, R. A., Stevens, A. N., and Griffiths, J. R. NMR studies of metabolites

1981.